Biological correlates of blood pressure variability in elderly at high risk of cardiovascular disease.

BACKGROUND Visit-to-visit variability in blood pressure is an independent predictor of cardiovascular disease. This study investigates biological correlates of intra-individual variability in blood pressure in older persons. METHODS Nested observational study within the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) among 3,794 male and female participants (range 70-82 years) with a history of, or risk factors for cardiovascular disease. Individual visit-to-visit variability in systolic and diastolic blood pressure and pulse pressure (expressed as 1 SD in mm Hg) was assessed using nine measurements over 2 years. Correlates of higher visit-to-visit variability were examined at baseline, including markers of inflammation, endothelial function, renal function and glucose homeostasis. RESULTS Over the first 2 years, the mean intra-individual variability (1 SD) was 14.4mm Hg for systolic blood pressure, 7.7mm Hg for diastolic blood pressure, and 12.6mm Hg for pulse pressure. After multivariate adjustment a higher level of interleukin-6 at baseline was consistently associated with higher intra-individual variability of blood pressure, including systolic, diastolic, and pulse pressure. Markers of endothelial function (Von Willebrand factor, tissue plasminogen activator), renal function (glomerular filtration rate) and glucose homeostasis (blood glucose, homeostatic model assessment index) were not or to a minor extent associated with blood pressure variability. CONCLUSION In an elderly population at risk of cardiovascular disease, inflammation (as evidenced by higher levels of interleukin-6) is associated with higher intra-individual variability in systolic, diastolic, and pulse pressure.

[1]  R. Kronmal,et al.  Blood pressure variability and the risk of all-cause mortality, incident myocardial infarction, and incident stroke in the cardiovascular health study. , 2013, American journal of hypertension.

[2]  N. Sattar,et al.  Association of visit-to-visit variability in blood pressure with cognitive function in old age: prospective cohort study , 2013, BMJ.

[3]  N. Sattar,et al.  Circulating interleukin‐6 concentration and cognitive decline in old age: the PROSPER study , 2013, Journal of internal medicine.

[4]  J. Kretzschmar,et al.  VISIT-TO-VISIT AND 24-H BLOOD PRESSURE VARIABILITY: ASSOCIATION WITH ENDOTHELIAL AND SMOOTH MUSCLE FUNCTION IN AFRICAN AMERICANS , 2013, Journal of Human Hypertension.

[5]  J. Wouter Jukema,et al.  Blood Pressure Variability and Cardiovascular Risk in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) , 2012, PloS one.

[6]  M. Hsieh,et al.  Visit‐to‐visit variability in blood pressure strongly predicts all‐cause mortality in patients with type 2 diabetes: a 5·5‐year prospective analysis , 2012, European journal of clinical investigation.

[7]  H. Rakugi,et al.  The impact of visit-to-visit variability in blood pressure on renal function , 2012, Hypertension Research.

[8]  S. Oparil,et al.  Reproducibility of visit-to-visit variability of blood pressure measured as part of routine clinical care , 2011, Journal of hypertension.

[9]  N. Sattar,et al.  C-Reactive Protein and Genetic Variants and Cognitive Decline in Old Age: The PROSPER Study , 2011, PloS one.

[10]  D. Leys,et al.  Relationship Between Baseline Blood Pressure Parameters (Including Mean Pressure, Pulse Pressure, and Variability) and Early Outcome After Stroke: Data From the Tinzaparin in Acute Ischaemic Stroke Trial (TAIST) , 2011, Stroke.

[11]  K. Reynolds,et al.  The Relationship Between Visit-to-Visit Variability in Systolic Blood Pressure and All-Cause Mortality in the General Population: Findings From NHANES III, 1988 to 1994 , 2011, Hypertension.

[12]  E. O’Brien,et al.  Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension , 2010, The Lancet.

[13]  P. Rothwell,et al.  Limitations of the usual blood-pressure hypothesis and importance of variability, instability, and episodic hypertension , 2010, The Lancet.

[14]  N. Sattar,et al.  Activation of Hemostasis and Decline in Cognitive Function in Older People , 2010, Arteriosclerosis, Thrombosis and Vascular Biology.

[15]  P. Rothwell,et al.  Reproducibility of Measures of Visit-to-Visit Variability in Blood Pressure after Transient Ischaemic Attack or Minor Stroke , 2009, Cerebrovascular Diseases.

[16]  P. Macfarlane,et al.  Are Markers of Inflammation More Strongly Associated with Risk for Fatal Than for Nonfatal Vascular Events? , 2009, PLoS medicine.

[17]  M. Emdin,et al.  Awake Blood Pressure Variability, Inflammatory Markers and Target Organ Damage in Newly Diagnosed Hypertension , 2008, Hypertension Research.

[18]  Renata Cifkova,et al.  Erratum: Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension and of the European Society of Cardiology (Journal of Hypertension (2007) 25, (1105-1187)) , 2007 .

[19]  A. Dominiczak,et al.  2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) , 2007, European heart journal.

[20]  P. Deyn,et al.  Stroke severity, early recovery and outcome are each related with clinical classification of stroke: Data from the ‘Tinzaparin in Acute Ischaemic Stroke Trial’ (TAIST) , 2007, Journal of the Neurological Sciences.

[21]  P. Macfarlane,et al.  C-Reactive Protein and Prediction of Coronary Heart Disease and Global Vascular Events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) , 2007, Circulation.

[22]  A. Dominiczak,et al.  2007 ESH‐ESC Guidelines for the management of arterial hypertension , 2007 .

[23]  D. Su.  Treatment of hypertension based on measurement of blood pressure variability: lessons from animal studies , 2006, Current opinion in cardiology.

[24]  Daniel W. Jones,et al.  Recommendations for blood pressure measurement in humans and experimental animals: Part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. , 2005, Hypertension.

[25]  C. Bulpitt,et al.  Systolic blood pressure variability as a risk factor for stroke and cardiovascular mortality in the elderly hypertensive population , 2003, Journal of hypertension.

[26]  Daniel W. Jones,et al.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. , 2003, Hypertension.

[27]  P. Macfarlane,et al.  Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial , 2002, The Lancet.

[28]  Y. Imai,et al.  Office blood pressure variability as a predictor of acute myocardial infarction in elderly patients receiving antihypertensive therapy , 2002, Journal of Human Hypertension.

[29]  D. Su,et al.  Arterial Baroreflex Deficit Induced Organ Damage in Sinoaortic Denervated Rats , 2001, Journal of cardiovascular pharmacology.

[30]  Y. Imai,et al.  Office blood pressure variability as a predictor of brain infarction in elderly hypertensive patients. , 2000, Hypertension research : official journal of the Japanese Society of Hypertension.

[31]  N. Nagelkerke,et al.  Estimating the prevalence of hypertension corrected for the effect of within-person variability in blood pressure. , 2000, Journal of clinical epidemiology.

[32]  A. Folsom,et al.  Low Heart Rate Variability in a 2-Minute Rhythm Strip Predicts Risk of Coronary Heart Disease and Mortality From Several Causes: The ARIC Study , 2000, Circulation.

[33]  P. Macfarlane,et al.  The design of a prospective study of Pravastatin in the Elderly at Risk (PROSPER). PROSPER Study Group. PROspective Study of Pravastatin in the Elderly at Risk. , 1999, The American journal of cardiology.

[34]  A. Levey,et al.  A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.

[35]  R. Nadeau,et al.  Effects of antihypertensive therapies on the sympathetic nervous system. , 1999, The Canadian journal of cardiology.

[36]  D. Reed,et al.  Variability in systolic blood pressure--a risk factor for coronary heart disease? , 1997, American journal of epidemiology.

[37]  P. Nilsson,et al.  Increased levels of tissue plasminogen activator antigen in essential hypertension. A population‐based study in Sweden , 1997, Journal of hypertension.

[38]  P. Ridker,et al.  Endogenous tissue-type plasminogen activator and risk of myocardial infarction , 1993, The Lancet.

[39]  N. Cook,et al.  Screening rules for determining blood pressure status in clinical trials: Application to the trials of hypertension prevention , 1992 .

[40]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[41]  K. Diaz,et al.  Relationship of visit-to-visit and ambulatory blood pressure variability to vascular function in African Americans , 2012, Hypertension Research.

[42]  Benjamin J. Epstein,et al.  Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure , 2007 .

[43]  John Norrie,et al.  Current Controlled Trials in Cardiovascular Medicine a Prospective Study of Pravastatin in the Elderly at Risk (prosper): Screening Experience and Baseline Characteristics , 2002 .

[44]  N. Nagelkerke,et al.  Influence of correction for within-person variability in blood pressure on the prevalence, awareness, treatment, and control of hypertension. , 2000, American journal of hypertension.

[45]  N. Doba,et al.  Relationship between endothelial function and fibrinolysis in early hypertension. , 1998, HYPERTENSION.

[46]  B. Rosner,et al.  The implications of blood pressure variability for clinical and screening purposes. , 1979, Journal of chronic diseases.